Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
about
Current management and prognostic features for gastrointestinal stromal tumor (GIST)A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Is there something other than imatinib mesilate in therapeutic options for GIST?The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTRecent advances and novel agents for gastrointestinal stromal tumor (GIST)Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors.Management of gastrointestinal stromal tumors.Regorafenib for treatment of advanced gastrointestinal stromal tumors.Efficacy of motesanib diphosphate in non-small-cell lung cancer.Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.Growth Factors and COX2 Expression in Canine Perivascular Wall Tumors.
P2860
Q28391684-6C5EB426-3436-49B0-AA86-C1390C9920C8Q30414010-12D8CEEE-719A-4B00-A8CB-DEAA97531049Q33807742-42BE2CFA-499B-4C0A-902B-87F8F03E95C0Q34046157-506D94DF-0492-4C1F-8D51-AECDEB80DC7DQ34207379-77CA8A5C-5169-4B79-8D50-DE40A28093BFQ34725749-361D46F4-E444-48CC-B46A-3B95D7C286C5Q36015295-E6D24D2E-37CB-43A0-A665-F24CFB3F8876Q36118178-A429BBD3-1E1C-4975-B04A-363A05B45510Q36125976-4435A1E6-D559-4C93-A0AA-C67DB9F1FB1CQ36180074-A5F5FF2C-7583-4AF2-8C6F-FC323464D1B7Q37944803-00438FC7-DCA9-47AE-8B07-63BAEBDBCFD2Q38081983-EAC7DC3D-F754-4371-AEBC-F6C0D64FF6FFQ38176966-CA4A1087-351A-4673-B1A4-F45082BDE0E0Q38230556-8AD5066A-45C4-4C77-B48B-02AE0112A9A3Q38266025-56EE5415-9580-4899-A29B-ECC72FB7919AQ38268165-45ED836C-7117-4B1A-91E0-09AB19378A29Q38323440-CEE1E8D4-CEE1-40A5-8737-4066C65B64D9Q38527941-20066CB8-C15A-4943-A481-52322866700EQ38759141-5718557C-651B-4494-AD47-00F47FFEB4E3Q39127820-08E99164-E51B-45AD-BB96-BF17F0A4B96BQ44640459-905E99B6-126F-4004-AA3B-400EAAC77AC3Q47097647-A6F59644-B482-442B-B0BA-2F0A6435590EQ50161676-27CD8F1E-19D3-42AE-ACB3-70C2C18326DEQ53335025-76C03271-AEC4-4FC9-BDBE-DA2A35000FC7Q54283149-423501C7-A265-496F-B39B-E2BF7F85432A
P2860
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@ast
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@en
type
label
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@ast
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@en
prefLabel
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@ast
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@en
P2093
P2860
P1476
Efficacy and safety of motesan ...... strointestinal stromal tumors.
@en
P2093
Allan Van Oosterom
Binh Nguyen Bui
Daniel E Stepan
Justus Duyster
Jörg Thomas Hartmann
Keith Skubitz
Laurence Baker
Lee S Rosen
Peter Reichardt
Robert S Benjamin
P2860
P2888
P356
10.1007/S00280-010-1431-9
P577
2010-09-14T00:00:00Z